IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11951133 B1

PDFFull Text
Date of Patent:
Apr. 09, 2024

Filed:

Jul. 13, 2022

3-substituted piperidine compounds for cbl-b inhibition, and use thereof

Applicant:

Nurix Therapeutics, Inc., San Francisco, CA (US);

Inventors:

Arthur T. Sands, San Francisco, CA (US);

Neil F. Bence, San Francisco, CA (US);

Christoph W. Zapf, San Francisco, CA (US);

Frederick Cohen, San Francisco, CA (US);

Chenbo Wang, San Francisco, CA (US);

Thomas Cummins, San Francisco, CA (US);

Hiroko Tanaka, San Francisco, CA (US);

Hunter Shunatona, Oakland, CA (US);

Mario Cardozo, San Francisco, CA (US);

Dahlia Weiss, San Mateo, CA (US);

Jennifa Gosling, San Francisco, CA (US);

Assignee:

NURIX THERAPEUTICS, INC., San Francisco, CA (US);

Attorney:

Squire Patton Boggs (US) LLP

Primary Examiner:

Nizal S Chandrakumar

Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 31/438 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 33/243 (2019.01); A61K 35/761 (2015.01); A61K 35/763 (2015.01); A61K 35/768 (2015.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 491/107 (2006.01); C07F 5/02 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/438 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 33/243 (2019.01); A61K 35/761 (2013.01); A61K 35/763 (2013.01); A61K 35/768 (2013.01); A61K 38/193 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61N 5/1001 (2013.01); A61N 5/1077 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 491/107 (2013.01); C07F 5/022 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5152 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01);
Abstract

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

Find Patent Forward Citations

Loading…